Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
128 stopped studies mapped to Transitional Cell Carcinoma and descendants · 93% state a reason
Over the 128 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05894447 | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in… | Phase 1 | withdrawn | Jun 8, 2023 | Weill Medical College of Cornell University | Insufficient funding | Funding |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With… | Phase 2 | terminated | Oct 5, 2016 | M.D. Anderson Cancer Center | The study was terminated early by the Sponsor | Other (stated, no rule matched) |
| NCT04197986 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial…(PROOF302) | Phase 3 | terminated | Dec 13, 2019 | QED Therapeutics, a BridgeBio company | The sponsor has decided to close the study due to the discontinuation of infigratinib development.… | Safety / toxicity |
| NCT06018116 | A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for…(CANUCK-01) | Phase 2 | withdrawn | Aug 30, 2023 | CHU de Quebec-Universite Laval | Results of EV302 study do not make it feasible to complete a study in second line avelumab… | Other (stated, no rule matched) |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants… | Phase 1 / Phase 2 | terminated | Jun 20, 2019 | pharmaand GmbH | Due to a change in development priorities, no further clinical development of the lucitanib plus… | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT04341740 | Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma(WindMIL-001) | N/A | terminated | Apr 10, 2020 | University of Oklahoma | Study funding was withdrawn. | Funding |
| NCT02887248 | Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or… | Phase 2 | terminated | Sep 2, 2016 | SCRI Development Innovations, LLC | Enrollment issues | Enrollment / accrual |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer… | N/A | terminated | Aug 22, 2018 | University of Washington | Enrollment ended early due to the funding timeline | Enrollment / accrual |
| NCT01215136 | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced… | Phase 2 | terminated | Oct 6, 2010 | Matthew Galsky | Lack of Accrual | Enrollment / accrual |
| NCT02232646 | A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies | Phase 2 | withdrawn | Sep 5, 2014 | Sumitomo Pharma America, Inc. | Low feasibility | Other (stated, no rule matched) |
| NCT06050954 | A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder…(CARMA) | Phase 2 | withdrawn | Sep 22, 2023 | Fox Chase Cancer Center | Change in standard of care. | Other (stated, no rule matched) |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT03737123 | Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in… | Phase 2 | terminated | Nov 9, 2018 | Nabil Adra | Lack of accrual | Enrollment / accrual |
| NCT03912818 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant… | Phase 2 | terminated | Apr 11, 2019 | Stanford University | Difficulty with enrollment | Enrollment / accrual |
| NCT03606174 | A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens… | Phase 2 | terminated | Jul 30, 2018 | Mirati Therapeutics Inc. | The study was terminated due to sponsor decision / portfolio prioritization, and not due to safety… | Safety / toxicity |
| NCT04039867 | Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer | Phase 2 | terminated | Jul 31, 2019 | University of California, Irvine | Trial was terminated due to halt in funding. | Funding |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous… | Phase 1 / Phase 2 | terminated | Nov 20, 2020 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT03927573 | Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer… | Phase 1 | terminated | Apr 25, 2019 | AvenCell Europe GmbH | business decision by sponsor | Sponsor / business decision |
| NCT02450331 | A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With…(IMvigor010) | Phase 3 | terminated | May 21, 2015 | Hoffmann-La Roche | Sponsor decided to terminate the study early because the study did not meet its primary endpoint… | Safety / toxicity |
| NCT03397394 | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma(ATLAS) | Phase 2 | terminated | Jan 12, 2018 | pharmaand GmbH | Efficacy did not meet the continuance criteria and DMC recommended to stop enrollment. | Efficacy / futility |
| NCT05107427 | Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma(AVENU) | Phase 2 | withdrawn | Nov 4, 2021 | 4D pharma plc | Sponsor unable to proceed | Other (stated, no rule matched) |
| NCT05496192 | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma… | Phase 2 | withdrawn | Aug 11, 2022 | Bristol-Myers Squibb | Replaced it with another clinical trial | Other (stated, no rule matched) |
| NCT03265080 | A Study of ADXS-NEO Expressing Personalized Tumor Antigens(NEO) | Phase 1 | terminated | Aug 29, 2017 | Advaxis, Inc. | Business decision | Sponsor / business decision |
| NCT05052372 | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving… | — | terminated | Sep 22, 2021 | xCures | Sponsor request to terminate study due to enrollment numbers | Enrollment / accrual |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based… | Phase 1 / Phase 2 | terminated | Apr 20, 2021 | Xennials Therapeutics Australia Pty Ltd | Study was terminated by IP Holder (collaborator), PinotBio Inc. | Other (stated, no rule matched) |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | Rubius Therapeutics | The Sponsor terminated study after dosing 2 dose groups (7 pts) and closed trial on 11/30/22.… | Other (stated, no rule matched) |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT04972253 | Phase I BLASST-3 Trial((BLASST)-3) | Phase 1 | withdrawn | Jul 22, 2021 | Guru P. Sonpavde | Low Accrual | Enrollment / accrual |
| NCT02901548 | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial… | Phase 2 | terminated | Sep 15, 2016 | H. Lee Moffitt Cancer Center and Research Institute | Study closed early due to futility | Efficacy / futility |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer… | Phase 1 | terminated | Nov 21, 2019 | Augusta University | Closed by IRB on 3/28/22 | Other (stated, no rule matched) |
| NCT03266900 | A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma…(RESECT) | Early Phase 1 | terminated | Aug 30, 2017 | University Health Network, Toronto | Difficulties with accrual | Enrollment / accrual |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2022 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT04960956 | Glycosylation of Exosomes in Prostate and Urothelial Carcinoma | — | terminated | Jul 14, 2021 | Indiana University | Could not identify a replacement Principal Investigator. | Investigator |
| NCT04179110 | Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With… | Phase 2 | withdrawn | Nov 27, 2019 | Yale University | Funding was withdrawn prior to first enrollment. | Enrollment / accrual |
| NCT01093066 | Prospective Multicentric Evaluation of a Bladder Preservation Strategy(ReChiVe) | Phase 2 | terminated | Mar 25, 2010 | Centre Hospitalier Universitaire de Saint Etienne | Difficulties in the inclusion and follow-up of patients | Other (stated, no rule matched) |
| NCT03287050 | Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial… | Phase 2 | terminated | Sep 19, 2017 | University of Michigan Rogel Cancer Center | due to changing therapeutic landscape in metastatic bladder cancer and lack of… | Other (stated, no rule matched) |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or… | Phase 1 | terminated | May 11, 2016 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic… | Phase 2 | terminated | Apr 14, 2017 | Weill Medical College of Cornell University | Lack of accrual | Enrollment / accrual |
| NCT04066595 | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.(CabUC) | Phase 2 | terminated | Aug 26, 2019 | Johannes Gutenberg University Mainz | Recruitment problems | Enrollment / accrual |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for… | Phase 2 | terminated | Oct 8, 2020 | Latin American Cooperative Oncology Group | Not approved | Other (stated, no rule matched) |
| NCT02693717 | Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial… | Phase 2 | terminated | Feb 29, 2016 | M.D. Anderson Cancer Center | The trial was closed due to the changing efficacy of treatments for metastatic urothelial cancer. | Efficacy / futility |
| NCT01438112 | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer(BOND) | Phase 2 / Phase 3 | terminated | Sep 21, 2011 | CG Oncology, Inc. | Change in study design | Other (stated, no rule matched) |
| NCT02608125 | A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult… | Phase 1 | terminated | Nov 18, 2015 | Principia Biopharma, a Sanofi Company | focus portfolio on immune-mediated diseases | Sponsor / business decision |
| NCT02688348 | Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients… | N/A | withdrawn | Feb 23, 2016 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT03407976 | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies(APPEASE) | Phase 1 | terminated | Jan 23, 2018 | University of Utah | Funding source withdrew financial support prior to start of Phase II portion of study | Funding |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | Phase 2 | withdrawn | May 8, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Grant not approved | Other (stated, no rule matched) |
| NCT04006691 | Efficacy and Safety of UGN-101 in Recurrent Patients(Retreatment) | Phase 3 | withdrawn | Jul 5, 2019 | UroGen Pharma Ltd. | Due to projected low enrollment, it has decided not to move forward with the study. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Apr 12, 2024source: clinicaltrials